D0720000
Dexamethasone sodium phosphate
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Dexamethasone 21-phosphate disodium salt
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C22H28FNa2O8P
CAS Number:
Molecular Weight:
516.40
Beilstein:
6473066
EC Number:
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
dexamethasone
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
SMILES string
[Na+].[Na+].[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1(F)[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@@H](C)[C@]4(O)C(=O)COP([O-])([O-])=O
InChI
1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15+,16+,17+,19+,20+,21+,22+;;/m1../s1
InChI key
PLCQGRYPOISRTQ-FCJDYXGNSA-L
유전자 정보
human ... NR3C1(2908)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Dexamethasone sodium phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
이미 열람한 고객
Veysel Nijat Baş et al.
European journal of pediatrics, 171(4), 735-736 (2011-12-29)
Iatrogenic Cushing syndrome may occur as an undesirable outcome of high-dose glucocorticoids treatments. This may also cause hypothalamus-hypophysis-adrenal axis suppression. While this situation may be caused more frequently with oral and topical glucocorticoid therapy, iatrogenic Cushing syndrome in childhood, caused
Weina Liu et al.
Neuroscience letters, 524(2), 119-123 (2012-07-21)
Prenatal exposure to glucocorticoids (GCs) leads to affective dysfunction in adulthood, which may be associated with the alterations in hypothalamic-pituitary-adrenal (HPA) axis. Physical exercise has been shown to ameliorate depressive symptoms. The objectives of present study were to investigate whether
Marieke Veurink et al.
Pharmaceutical research, 30(4), 1176-1187 (2013-02-16)
To investigate the mechanism behind the aggregation breaking properties of dexamethasone phosphate and related corticosteroids on the IgG1 antibody bevacizumab (Avastin®). An in silico 3D dimer model is developed to identify the bevacizumab-bevacizumab interface, and different corticosteroids are docked onto
Martin Gräber et al.
ACS chemical biology, 6(10), 1008-1014 (2011-07-30)
Phosphorylation-dependent protein binding domains are crucially important for intracellular signaling pathways and thus highly relevant targets in chemical biology. By screening of chemical libraries against 12 structurally diverse phosphorylation-dependent protein binding domains, we have identified fosfosal and dexamethasone-21-phosphate as selective
Xiaolin Xu et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 249(10), 1503-1510 (2011-05-21)
To assess how safe and effective it is to use menthol as a permeability enhancer in ophthalmic drug delivery systems. In this study, the effect of menthol on permeability of dexamethasone disodium phosphate in the cornea and sclera was investigated
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.